Literature DB >> 16482609

Galantamine may improve attention and speech in schizophrenia.

Enrique L M Ochoa, Elizabeth Clark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16482609     DOI： 10.1002/hup.751

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN： 0885-6222            Impact factor:   1.672


× No keyword cloud information.
  6 in total

Review 1.  Cholinergic functioning in stimulant addiction: implications for medications development.

Authors:  Mehmet Sofuoglu; Marc Mooney
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

Review 2.  Cognitive function as an emerging treatment target for marijuana addiction.

Authors:  Mehmet Sofuoglu; Dawn E Sugarman; Kathleen M Carroll
Journal:  Exp Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.157

3.  Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.

Authors:  Dawn E Sugarman; Joao P De Aquino; James Poling; Mehmet Sofuoglu
Journal:  Pharmacol Biochem Behav       Date:  2019-05-10       Impact factor: 3.533

Review 4.  Cognitive enhancement as a pharmacotherapy target for stimulant addiction.

Authors:  Mehmet Sofuoglu
Journal:  Addiction       Date:  2010-01       Impact factor: 6.526

5.  The effects of galantamine on psychopathology in chronic stable schizophrenia.

Authors:  Robert R Conley; Douglas L Boggs; Deanna L Kelly; Robert P McMahon; Dwight Dickinson; Stephanie Feldman; M Patricia Ball; Robert W Buchanan
Journal:  Clin Neuropharmacol       Date:  2009 Mar-Apr       Impact factor: 1.592

Review 6.  Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Authors:  Enrique L M Ochoa; Jose Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.